DA Davidson Has Lowered Expectations for Paysign (NASDAQ:PAYS) Stock Price

Paysign (NASDAQ:PAYS – Get Free Report) had its target price decreased by research analysts at DA Davidson from $15.00 to $14.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. DA Davidson‘s target price indicates a potential upside of 42.06% from the company’s current price.

Several other brokerages also recently issued reports on PAYS. Weiss Ratings upgraded shares of Paysign from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Maxim Group downgraded Paysign from a “buy” rating to a “hold” rating in a research report on Wednesday. Barrington Research set a $15.00 price objective on Paysign in a research note on Tuesday, August 11th. Wall Street Zen cut Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Finally, Lake Street Capital raised their price objective on Paysign from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Paysign currently has an average rating of “Moderate Buy” and an average target price of $14.67.

Get Our Latest Report on Paysign

Paysign Trading Down 2.8%

Shares of NASDAQ PAYS traded down $0.28 during mid-day trading on Wednesday, hitting $9.86. The company had a trading volume of 970,745 shares, compared to its average volume of 755,393. The company has a market capitalization of $556.43 million, a PE ratio of 29.95 and a beta of 0.92. The firm has a 50-day simple moving average of $13.82 and a two-hundred day simple moving average of $8.63. Paysign has a one year low of $3.08 and a one year high of $16.15.

Paysign (NASDAQ:PAYS – Get Free Report) last released its earnings results on Monday, November 9th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Paysign had a return on equity of 37.20% and a net margin of 18.48%. The business had revenue of $30.80 million for the quarter, compared to the consensus estimate of $29.02 million. Sell-side analysts expect that Paysign will post 0.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mark Newcomer sold 50,000 shares of Paysign stock in a transaction on Friday, October 9th. The stock was sold at an average price of $15.34, for a total transaction of $767,000.00. Following the completion of the sale, the chief executive officer owned 9,113,002 shares of the company’s stock, valued at approximately $139,793,450.68. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joan Herman sold 38,900 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $11.74, for a total transaction of $456,686.00. Following the completion of the sale, the executive vice president directly owned 609,421 shares of the company’s stock, valued at approximately $7,154,602.54. The trade was a 6.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 259,904 shares of company stock worth $3,402,424 in the last 90 days. Company insiders own 24.50% of the company’s stock.

Institutional Trading of Paysign

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Paysign during the second quarter worth approximately $25,219,000. Punch & Associates Investment Management Inc. bought a new stake in shares of Paysign in the second quarter valued at approximately $16,983,000. Renaissance Technologies LLC grew its position in Paysign by 17.4% during the first quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock worth $9,033,000 after buying an additional 227,300 shares in the last quarter. AWM Investment Company Inc. acquired a new stake in Paysign during the second quarter worth approximately $6,560,000. Finally, Dimensional Fund Advisors LP grew its position in Paysign by 16.8% during the first quarter. Dimensional Fund Advisors LP now owns 575,619 shares of the company’s stock worth $3,396,000 after buying an additional 82,736 shares in the last quarter. Institutional investors own 25.89% of the company’s stock.

Top Paysign Stories

Here are a few of the latest stories about PAYS:

  • Positive Sentiment: Q3 revenue reached a record $30.8 million, up 42.6% year over year, while EPS of $0.11 beat the $0.09 consensus. Operating margin more than tripled to 23.8%, and pharma revenue rose 109.8%. Paysign Q3 2026 results
  • Negative Sentiment: Paysign’s FY 2026 EPS guidance of $0.37–$0.38 is below the $0.51 consensus, despite revenue guidance of $114 million–$117 million being broadly in line with the $114.7 million estimate. 2026 revenue and margin outlook
  • Negative Sentiment: A customer’s pullback is raising concerns about future revenue, and Maxim Group downgraded the stock from “buy” to “hold,” adding potential pressure after the earnings update. Customer pullback weighs on future revenue Maxim Group ratings

Paysign Company Profile

(Get Free Report)

Paysign, Inc. provides prepaid card programs, payment processing and related financial technology services. Its platform supports organizations that need to distribute funds and manage payments, including businesses in the healthcare sector. The company serves plasma collection centers with donor compensation and payment solutions, and works with pharmaceutical companies on patient assistance and affordability programs. Its services also support payments for clinical trials and other disbursement needs.

Featured Stories

Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.